CD4 and melanoma: Moreover, it has been shown that combinatorial immunotherapy using LB-100, a PP2A inhibitor together with PD-1 blockade further enhances CD4+ and CD8+ T cell-mediated antitumor immune responses in mouse melanoma model without inducing autoimmunity [40].